Imaging Modality Depending on the Levels of Tumor Markers

#2213

Introduction: 18 F-Fluorodihydroxyphenylalanine(18F)-FDOPA positron emission tomography (PET)/computed tomography (CT) has the advantage of being a noninvasive test and is by far the most promising imaging modality for neuroendocrine tumors (NETs).

Aim(s): The aim of this study is to present our experience between the correlation (18F)-FDOPA/PET-CT findings and elevated serum values of chromogranin A, serotonin and urinary excretion of 5-hydroxyindolacetic acid (5-HIAA) in patients with histologically verified (NETs).

Materials and methods: 29 patients (twenty gut, seven pancreas, one lung and one liver) were enrolled in our institution. Patients were separated in two groups according to those who had positive levels of tumors markers (15 patients) and those who had normal range levels of tumors markers (14 patients). All of them underwent PET-CT consisting of the injection of (18F)-FDOPA followed by 1 hour delayed PET of the whole body.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Iorio J

Authors: Iorio J, Eleta M, Cuneo L, Polillo D, Peña F,

Keywords: neuroendocrine tumors, tumor marker, 18F-FDOPA, PET/CT,

To read the full abstract, please log into your ENETS Member account.